Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.22
GLAXF's Cash to Debt is ranked higher than
51% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. GLAXF: 0.22 )
GLAXF' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.22

Equity to Asset 0.13
GLAXF's Equity to Asset is ranked lower than
53% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. GLAXF: 0.13 )
GLAXF' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.4
Current: 0.13

0.05
0.4
Interest Coverage 9.68
GLAXF's Interest Coverage is ranked higher than
57% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.95 vs. GLAXF: 9.68 )
GLAXF' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 9.68

0.81
28.06
F-Score: 6
Z-Score: 2.20
M-Score: -2.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 22.54
GLAXF's Operating margin (%) is ranked higher than
92% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.59 vs. GLAXF: 22.54 )
GLAXF' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 22.54

1.68
36.94
Net-margin (%) 17.63
GLAXF's Net-margin (%) is ranked higher than
91% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.31 vs. GLAXF: 17.63 )
GLAXF' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 17.63

5.76
23.94
ROE (%) 68.04
GLAXF's ROE (%) is ranked higher than
99% of the 874 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. GLAXF: 68.04 )
GLAXF' s 10-Year ROE (%) Range
Min: 17.3   Max: 244.21
Current: 68.04

17.3
244.21
ROA (%) 10.35
GLAXF's ROA (%) is ranked higher than
91% of the 910 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.02 vs. GLAXF: 10.35 )
GLAXF' s 10-Year ROA (%) Range
Min: 3.84   Max: 26.32
Current: 10.35

3.84
26.32
ROC (Joel Greenblatt) (%) 58.14
GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.17 vs. GLAXF: 58.14 )
GLAXF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.44   Max: 141.62
Current: 58.14

5.44
141.62
Revenue Growth (%) -0.90
GLAXF's Revenue Growth (%) is ranked higher than
62% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. GLAXF: -0.90 )
GLAXF' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 15.3
Current: -0.9

-1.5
15.3
EBITDA Growth (%) 17.60
GLAXF's EBITDA Growth (%) is ranked higher than
82% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. GLAXF: 17.60 )
GLAXF' s 10-Year EBITDA Growth (%) Range
Min: -12.1   Max: 17.6
Current: 17.6

-12.1
17.6
EPS Growth (%) 51.40
GLAXF's EPS Growth (%) is ranked higher than
94% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. GLAXF: 51.40 )
GLAXF' s 10-Year EPS Growth (%) Range
Min: -30.2   Max: 51.4
Current: 51.4

-30.2
51.4
» GLAXF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.80
GLAXF's P/E(ttm) is ranked higher than
92% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.00 vs. GLAXF: 16.80 )
GLAXF' s 10-Year P/E(ttm) Range
Min: 10.16   Max: 40.41
Current: 16.8

10.16
40.41
P/B 13.70
GLAXF's P/B is ranked higher than
51% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. GLAXF: 13.70 )
GLAXF' s 10-Year P/B Range
Min: 5.48   Max: 14.11
Current: 13.7

5.48
14.11
P/S 2.90
GLAXF's P/S is ranked higher than
76% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.96 vs. GLAXF: 2.90 )
GLAXF' s 10-Year P/S Range
Min: 1.94   Max: 4.21
Current: 2.9

1.94
4.21
PFCF 19.90
GLAXF's PFCF is ranked higher than
93% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 19.90 )
GLAXF' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 19.9

8.21
41.33
EV-to-EBIT 16.21
GLAXF's EV-to-EBIT is ranked higher than
88% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.72 vs. GLAXF: 16.21 )
GLAXF' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 240.2
Current: 16.21

7.7
240.2
PEG 6.92
GLAXF's PEG is ranked higher than
83% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 6.92 )
GLAXF' s 10-Year PEG Range
Min: 0.23   Max: 426.6
Current: 6.92

0.23
426.6
Shiller P/E 16.30
GLAXF's Shiller P/E is ranked higher than
95% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.40 vs. GLAXF: 16.30 )
GLAXF' s 10-Year Shiller P/E Range
Min: 10.59   Max: 20.59
Current: 16.3

10.59
20.59
Current Ratio 0.97
GLAXF's Current Ratio is ranked lower than
52% of the 891 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. GLAXF: 0.97 )
GLAXF' s 10-Year Current Ratio Range
Min: 0.97   Max: 1.78
Current: 0.97

0.97
1.78
Quick Ratio 0.69
GLAXF's Quick Ratio is ranked lower than
52% of the 890 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. GLAXF: 0.69 )
GLAXF' s 10-Year Quick Ratio Range
Min: 0.68   Max: 1.42
Current: 0.69

0.68
1.42

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.90
GLAXF's Dividend Yield is ranked higher than
98% of the 518 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. GLAXF: 5.90 )
GLAXF' s 10-Year Dividend Yield Range
Min: 2.72   Max: 5.91
Current: 5.9

2.72
5.91
Dividend Payout 0.93
GLAXF's Dividend Payout is ranked higher than
99% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 0.93 )
GLAXF' s 10-Year Dividend Payout Range
Min: 0.38   Max: 4.69
Current: 0.93

0.38
4.69
Dividend growth (3y) 6.40
GLAXF's Dividend growth (3y) is ranked higher than
81% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. GLAXF: 6.40 )
GLAXF' s 10-Year Dividend growth (3y) Range
Min: -12.6   Max: 20.8
Current: 6.4

-12.6
20.8
Yield on cost (5-Year) 8.08
GLAXF's Yield on cost (5-Year) is ranked higher than
97% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.46 vs. GLAXF: 8.08 )
GLAXF' s 10-Year Yield on cost (5-Year) Range
Min: 3.73   Max: 8.1
Current: 8.08

3.73
8.1
Share Buyback Rate 1.40
GLAXF's Share Buyback Rate is ranked higher than
90% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. GLAXF: 1.40 )
GLAXF' s 10-Year Share Buyback Rate Range
Min: 3.6   Max: -20
Current: 1.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.50
GLAXF's Price/DCF (Projected) is ranked higher than
91% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.00 vs. GLAXF: 1.50 )
GLAXF' s 10-Year Price/DCF (Projected) Range
Min: 0.97   Max: 3.75
Current: 1.5

0.97
3.75
Price/Median PS Value 1.00
GLAXF's Price/Median PS Value is ranked higher than
81% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. GLAXF: 1.00 )
GLAXF' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 2.57
Current: 1

0.69
2.57
Earnings Yield (Greenblatt) 6.40
GLAXF's Earnings Yield (Greenblatt) is ranked higher than
87% of the 893 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. GLAXF: 6.40 )
GLAXF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12.9
Current: 6.4

0.4
12.9
Forward Rate of Return (Yacktman) 5.60
GLAXF's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. GLAXF: 5.60 )
GLAXF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.6   Max: 68.7
Current: 5.6

2.6
68.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GSK.USA, GS7A.Germany, GS7.Germany, GSK N.Mexico, GSK.Argentina
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatric and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. Its products main categories are: Oral care, Nutritional, Total wellness, and Skin health. Its barands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.
» More Articles for GLAXF

Headlines

Articles On GuruFocus.com
Jeff Auxier Buys Berkshire Hathaway in Third Quarter Nov 18 2014 
Irving Kahn Starts New Position In GlaxoSmithKline Nov 13 2014 
Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014 Nov 12 2014 
Kahn Brothers' Third Quarter Numbers Nov 07 2014 
Tweedy Browne Global Value Fund's Top Picks for Q3 Oct 21 2014 
Diamond Hill Capital Comments on GlaxoSmithKline PLC Oct 17 2014 
Dodge & Cox’ Stock Fund Third Quarter 2014 Commentary Oct 16 2014 
Ebola: Is The Cure Out There? Oct 14 2014 
Guru Stocks at 52-Week Lows: GE, BHP, TOT, BP, GSK Oct 12 2014 
Guru Stocks at 52-Week Lows: BHP, GSK, UTX, SAP, TEF Sep 30 2014 

More From Other Websites
Merck buys rights to NewLink's Ebola vaccine Nov 24 2014
Bayer to use IPO proceeds to cut debt and buy consumer drugs Nov 24 2014
GSK shareholders to vote on Novartis deal on Dec. 18 Nov 24 2014
Cuban doctor to be flown to Geneva for Ebola care - Swiss Nov 19 2014
Reckitt Benckiser shareholders should sell new pharma shares Nov 18 2014
AstraZeneca lupus drug produces positive results in trial Nov 17 2014
No safety concerns yet in trials of GSK's Ebola vaccine Nov 17 2014
GlaxoSmithKline leads Access to Medicine Index Nov 16 2014
Bristol-Myers Squibb to build Irish biologics facility Nov 14 2014
US private equity outfit to bid for GlaxoSmithKline´s mature drugs business Nov 13 2014
Unanswered questions in Tesco’s accounting scandal Nov 06 2014
The unanswered questions in Tesco’s accounting scandal Nov 06 2014
GSK hepatitis C shot shows promise, bodes well for Ebola vaccines Nov 05 2014
Regus forecasts capex below estimates, eases fears over debt Oct 31 2014
Tesco Faces Criminal Probe Over Profits Crisis Oct 29 2014
SFO Launches Criminal Probe Into Tesco Crisis Oct 29 2014
Swiss test GSK Ebola vaccine in some volunteers going to Africa Oct 28 2014
GSK Nigeria 9-month pre-tax profit falls 25.9 pct Oct 28 2014
GSK shareholder-friendly policy shift could hurt credit profile, Fitch says Oct 27 2014
WHO vaccines boss signs up as Ebola trial guinea pig Oct 24 2014
U.S. tightens Ebola monitoring for West African visitors Oct 22 2014
GLOBAL MARKETS-Shares falter as Wall St tumbles; bond prices fall Oct 22 2014
[video] Pfizer considers AstraZeneca bid: Report Apr 21 2014
HICL Infrastructure: A Great Portfolio Diversifier With Attractive Yield Nov 27 2013

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK